Questioning Medicine

Kalapura C, et al. Triptan initiation and cerebrovascular events in patients with migraine: A nationwide cohort study. J Am Heart Assoc 2026 Feb 17; 15:e043409. DOI: 10.1161/JAHA.125.043409.
 
 
Today, we're talking triptans - those long-trusted migraine relievers - and a new study that asks a not-so-relaxing question: could they slightly raise the risk of ischemic stroke?
 
Let's break it down. Researchers analyzed data from 870,000 adults with migraine and no previous vascular events. The median age was 40, and about three-quarters were women. The team compared those who started triptans with those who didn't, adjusting carefully for age, health, and baseline risk factors.
 
Here's the headline number: over roughly seven years, people who started triptans had an ischemic stroke rate of 3.4 per 1000 person-years, compared to 1.7 per 1000 for nonusers. That's an absolute risk difference of just 0.17% per year, or, in practical terms, about one additional stroke for every 588 people treated annually.
 
So yes - there's a difference, but we're not talking about a massive public health crisis. It's more "tiny spark," not "raging inferno."
 
Now, the nuance. The patients in this analysis were relatively young and healthy. That small risk bump might carry more weight in older populations or in people with multiple vascular risk factors - things like hypertension, high cholesterol, or smoking. In other words, if you have a few checkmarks on the cardiovascular risk list, triptans may deserve a second thought before reaching for the prescription pad.
 
But for most migraine patients? Nothing earth-shattering here. Triptans remain highly effective and, for many, life-changing. The key phrase is informed decision-making.
 
As one clinician commented about the findings, it's all about balance: avoid triptans in patients with known cardiovascular disease, but for others, it's a reasonable discussion. If the medication helps someone reclaim their day from the grip of a migraine, a small increase in vascular risk may be worth it - as long as everyone's eyes are open to the trade-off.
 
It's another reminder that medicine rarely deals in absolutes. Every "yes" has a "maybe," and every prescription deserves a conversation - preferably one that doesn't start with a panicked Google search at 2 a.m.
 
So, the clinical takeaway: triptans may modestly increase ischemic stroke risk, but in context, they remain safe for most healthy migraine patients. Awareness matters more than alarm.

Li H-Y, et al. GLP-1 receptor agonists and risk of optic nerve or vision-threatening events in patients with type 2 diabetes or cardiometabolic diseases: A meta-analysis of randomized controlled trials. Diabetes Care 2026 Mar 1; 49:526. DOI: 10.2337/dc25-1929.
Heberer K, et al. New-onset nonarteritic anterior ischemic optic neuropathy and initiators of semaglutide in US veterans with type 2 diabetes. JAMA Ophthalmol 2026 Feb 12; [e-pub]. DOI: 10.1001/jamaophthalmol.2025.6262.
Noh Y, et al. Glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes. Diabetes Care 2026 Feb 17; [e-pub]. DOI: 10.2337/dc25-2577.
 
 
 
 
Nonarteritic anterior ischemic optic neuropathy is the kind of diagnosis that makes every clinician's stomach drop: sudden, often permanent vision loss, and not much we can do about it. It has always been rare, but a growing body of work is now pointing to a possible link with one of the most widely discussed drug classes in medicine: GLP-1 receptor agonists.
 
Three new studies add fuel to that conversation. First, a large meta-analysis pooled 20 randomized trials with about 80,000 participants-mostly people with type 2 diabetes followed for roughly three years. In that dataset, GLP-1 agonists did not increase a composite of serious ocular events and did not show a signal for ischemic optic neuropathy specifically. On the surface, that sounds reassuring.
 
But the observational data tell a more worrying story. In a U.S. veterans cohort of around 100,000 patients with type 2 diabetes already on metformin, investigators compared add-on semaglutide to add-on empagliflozin over a median of two years. The rate of NAION was higher with semaglutide-about 123 versus 67 events per 100,000 person-years. A separate analysis using a U.K. primary care database of roughly 500,000 people with type 2 diabetes found a similar pattern: those starting a GLP-1 agonist had a higher 1-year risk of NAION than those starting a DPP-4 inhibitor (18.5 vs. 7.2 events per 100,000 person-years).
 
These new results line up with prior observational work suggesting roughly a doubling of NAION incidence among GLP-1 users. So why the disconnect with the meta-analysis of randomized trials? It's almost certainly about design rather than biology. None of the trials were built to capture rare, unexpected eye events: vision outcomes weren't prespecified, routine eye exams weren't mandated, and the definitions of ocular safety events were inconsistent. In that setting, a signal as uncommon as NAION can easily be undercounted or missed entirely.
 
What should clinicians do with this? For most patients, the cardiometabolic benefits of GLP-1 agonists will still far outweigh a very small absolute risk of a rare optic neuropathy. But when we start or continue these drugs, especially in patients who already have vascular risk factors for eye disease, it's reasonable to add one more line to the counseling script: there is a rare association with NAION, and any sudden change in vision warrants urgent evaluation. This isn't a reason to abandon GLP-1s-but it is a reminder that even our most promising therapies can carry risks we only discover once they're widely used.

CME-- Discharge Questions Answered in 2025

Lin Z, et al. Antifibrotic drug finerenone restores fertility in premature ovarian insufficiency. Science 2026 Feb 5; 391:eadz4075. DOI: 10.1126/science.adz4075.
 
Premature ovarian insufficiency is usually one of those diagnoses that shuts the door on fertility: ovarian function is lost before age 40, mature follicles are scarce to nonexistent, and we have no reliable way to turn things back on. In most textbooks, that's the end of the story.
 
A group in Hong Kong is now asking a different question: what if the problem isn't just the follicles, but the neighborhood they live in? In aged mice, they found that the ovarian stroma becomes fibrotic and stiff, and that this mechanical stiffness itself seems to suppress follicle maturation. Loosen up the stroma, and previously dormant follicles begin to wake up.
 
To turn that concept into something clinically relevant, the team screened nearly 1,300 drugs that are already approved for other human uses, looking for agents that could activate follicles in mice. Ten made the cut. One of them, finerenone-an oral nonsteroidal mineralocorticoid receptor antagonist better known to nephrologists and cardiologists-also reduced collagen production in the ovarian stroma, effectively softening the tissue environment.
 
That observation led to a small, first-in-human trial. Fourteen women with POI-associated infertility received finerenone 20 mg twice weekly, with monthly ultrasound monitoring. Over 3 to 7 months, follicular development was seen in all participants, and eight produced mature oocytes. IVF was attempted when possible, and early embryos were obtained in three women; longer-term follow-up and pregnancy outcomes are still pending.
 
It's a fascinating mechanobiology story: instead of stimulating the follicle directly with gonadotropins or growth factors, the intervention targets the physical properties of the follicular niche. But there are important caveats. The study is tiny, uncontrolled, and POI is not an absolute guarantee of infertility-spontaneous ovulation and pregnancy do occasionally occur. Without a control group and without live-birth data, we cannot know yet how much of this signal represents true drug effect versus background noise.
 
For now, finerenone should stay firmly in the realm of clinical trials when it comes to fertility. But conceptually, this work opens a new front: treating infertility not just as an endocrine or genetic problem, but as a disease of tissue mechanics. If future studies confirm these findings, we may be looking at the beginnings of a paradigm shift in how we think about "irreversible" ovarian failure-and a new source of hope for patients who today are told their options are exhausted.

Stavropoulou E, et al. Reassessing the 2023 International Society for Cardiovascular Infectious Diseases Duke clinical criteria for infective endocarditis: Impact of excluding fever and updating diagnostic definitions. Clin Infect Dis 2025 Dec 31; [e-pub]. DOI: 10.1093/cid/ciaf737.
 
 Big takeaways

About 35% of patients truly had IE.

Fever showed up in 80% of patients both with and without IE, so it did not help distinguish them.

Dropping fever from the criteria actually made them better:

 

Sensitivity improved: 77% (no-fever) vs 74% (standard).

Specificity improved a lot: 80% vs 49%.

"Possible IE" shrank from 39% to 17%, meaning fewer gray-zone cases.

Only 0.4% of patients without IE were incorrectly labeled as having IE.

 

Both are widely used and both can work for regular (non-crusted) scabies.
 
The SCRATCH trial: who won?
In the SCRATCH trial from France, researchers treated about 1000 people in 300 households with confirmed scabies. Each household was randomized to:
 
Whole-body 5% permethrin cream on days 0 and 10, or
Oral ivermectin (weight-based) on days 0 and 10.
They then checked who was cured at day 28.
 
Here's what they found:
Household cure rates
Permethrin: 88% cured
Ivermectin: 72% cured
Translation: For every 6 households treated with permethrin instead of ivermectin, one extra household was fully cured (NNT  6).
 
Index (main) patient cure rates
Permethrin: 92%
Ivermectin: 77%
That's one extra person cured for about every 7 treated with permethrin instead of ivermectin (NNT  7).
 
Side effect
Skin irritation-type reactions: 14% with permethrin vs 10% with ivermectin.
So permethrin wins on cure, with a small trade-off in local skin reactions.